Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
June 09 2023 - 4:05PM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that the Company’s 2023 Annual Meeting of
Shareholders (Annual Meeting) was convened and adjourned, without
any business being conducted, due to lack of the required quorum.
A quorum consists of the presence at the Annual Meeting either
online during the live audio webcast or represented by proxy of the
holders of a majority of the voting power of our outstanding shares
of common stock entitled to vote at the Annual Meeting. There were
fewer than a majority of shares entitled to vote present, either in
person or by proxy at the Annual Meeting. The Annual Meeting
therefore had no quorum, and accordingly, the Annual Meeting has
been adjourned. The Annual Meeting will resume with respect to all
proposals at 11 a.m. Eastern Time on Friday, June 23, 2023 and will
continue to be held virtually.
The record date for determining shareholders eligible to vote at
the Annual Meeting will remain the close of business on April 13,
2023. Shareholders who have already submitted a proxy do not need
to vote again for the reconvened Annual Meeting, as the proxies
submitted will remain valid. Shareholders who have already
submitted proxies and would like to change their vote with respect
to any of the proposals can update their vote in the manner set
forth in the Definitive Proxy Statement. Your vote will be recorded
at the Annual Meeting in accordance with your most recently
submitted proxy.
Ocugen shareholders as of close of business on the April
13, 2023 record date who have not yet voted are encouraged to vote
online at www.proxyvote.com or by telephone at 1-800-690-6903.
Shareholders that need assistance voting or have questions, may
contact Ocugen’s proxy solicitation firm, Innisfree M&A
Incorporated, at (877) 750-8198.
Voting on all proposals will be open until the conclusion of
Ocugen’s 2023 Annual Meeting on June 23, 2023.
If you hold your shares of our common stock with a broker, bank,
or other holder of record as nominee or agent, you may be subject
to an earlier voting deadline and you should carefully review any
materials received from the nominee or agent regarding how to vote
your shares.
A copy of the Definitive Proxy Statement is available to
shareholders on the Company’s website and at the website maintained
by the SEC at www.sec.gov.
Ocugen shareholders as of the April 13, 2023 record date for the
Annual Meeting are invited to attend the virtual Annual Meeting by
visiting www.virtualshareholdermeeting.com/OCGN2023.
Important Information
This material may be deemed to be solicitation material in
respect of the Annual Meeting to be reconvened and held on June 23,
2023. In connection with the Annual Meeting, the Company filed a
Definitive Proxy Statement with the SEC on April 20, 2023. BEFORE
MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO READ THE
DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED
WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE
ANNUAL MEETING. The Definitive Proxy Statement was mailed to
shareholders who are entitled to vote at the Annual Meeting. No
changes have been made to the proposals to be voted on by
shareholders at the Annual Meeting. The Company’s Definitive Proxy
Statement and any other materials filed by the Company with the SEC
can be obtained free of charge at the SEC's website at www.sec.gov
or the Company’s website www.ocugen.com.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patient’s lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more at
www.ocugen.com and follow us on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks, and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact: Tiffany
HamiltonHead of Corporate Communications
IR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Sep 2023 to Sep 2024